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be analysed. Mean age of patients was 53.1 years and the gender ratio (female to 
male) was 5.8. The mean duration of disease was 14.7 years. While at time of diag-
nosis, 83.6% of patients declared they were employed, the employment rate at the 
time of the survey was of 49.9%, 7 points lower than that of the French general popu-
lation adjusted for age and gender (p  0.001). A total of 38.3% declared to be on 
part-time job while this rate is only of 28.4% in the French general population (p  
0.05). 67.5% of patients who were or have been employed reported that the disease 
had a negative impact on their professional career (up to 92.6% for severe RA). The 
two main impacts reported were on their job choices and discrimination during their 
career. 61.4% considered that it resulted in income losses. The work productivity 
impairment was high (23.4% and up to 52.5% for severe RA, p  0.001) mostly due 
to impairment while working (presenteeism) rather than absenteeism. Finally, patients’ 
estimation of their RA-work income loss is about a600 per month, which is not com-
pensated by disability pensions (a223 per month on average). CONCLUSIONS: These 
results reﬂect both the objective and the subjective negative impact of RA on working 
status and conditions, even in a country with substantial social support and extensive 
health coverage.
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OBJECTIVES: To describe the disease management and the cost of patients presenting 
a diagnosis of low back pain in the hospital perspective. METHODS: We performed 
a local data base request from the medical information system (PMSI) of the university 
hospital of Montpellier. We considered 3 consecutive years (2006,2007,2008) which 
allow us to get a follow-up and a traceability of patients over this period. We analyzed 
a group of 18–50 years old patients admitted across acute care, day care or mid-term 
care sectors with the following diagnosis codes M 545, M 512 of the ICD-10. 
RESULTS: A total of 583 patients were selected over the period representing a total 
of 1674 admissions (i.e.: 2.8 admissions per patient). The mean o SD age was 39 o 8 
years and female represent 56% of the patients. We observed 195 admissions in acute 
care (“less than 24 h” admissions excluded) with a mean length of stay of 5 o 4.5 
days. Day-care represents 47% of the admission in acute care sector. We observed 
271 admissions in mid-term care with a mean length of stay of 8 o 5.8 days. Few 
patients (6.8 %) were admitted consecutively in acute care and in mid term care 
thereafter. Surgery was the reason of ﬁrst admission for 13 patients. The cost is esti-
mated at 1,391 euros per patient admitted in acute care sector. CONCLUSIONS: In 
our sample, we noted a high rate of admission per patient for diagnosis or physical 
therapy reasons as the main pattern of low back pain management in-hospital. Admis-
sions for surgery were marginal. Overview of real practices in-hospital sector is key 
information to determine the medical need in this active patient population. Innovative 
medical device would minimize the burden of disease by reducing the number of day 
lost in-hospital and the time to return to work.
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OBJECTIVES: To describe the disease management and the cost of patients presenting 
a diagnosis of lumbago-sciatica in the hospital perspective. METHODS: We per-
formed a local data base request from the medical information system (PMSI) of the 
university hospital of Montpellier. We considered 3 consecutive years (2006,2007,2008) 
which allow us to get a follow-up and a traceability of patients over this period. We 
analyzed a group of 18–50 years old patients admitted across acute care, day care or 
mid-term care sectors with the diagnosis code M 511 of the ICD-10. Distribution of 
DRG’s was also analyzed and a weighed calculation was performed for the cost per 
patient in acute care sector. RESULTS: A total of 503 patients were selected over the 
period representing a total of 598 admissions (i.e.: 1.18 admissions per patient). The 
mean o SD age was 39.2 o 7.4 years and female represent 42% of the patients. We 
observed 488 admissions in acute care (“less than 24 h” admissions excluded) with a 
mean length of stay of 6.4 o 4 days. Day-care represents 4.8% of the admission in 
acute care sector. We observed 5 admissions in mid-term care and few patients (0.6 
%) were admitted consecutively in acute care and in mid term care thereafter. 418 
patients underwent surgery during their stay in acute care sector. The cost is estimated 
at 3,751 euros per patient admitted in acute care sector. CONCLUSIONS: In this 
population of patient, surgery is the main pattern of care and the main driver of cost. 
Innovative medical device would minimize the burden of disease by reducing or delay-
ing the number of surgeries. Nevertheless, additional information from the ambulatory 
care sector would be useful to describe the complete lumbago-sciatica management 
and to deﬁne the medical need for innovations in this active patient population.
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OBJECTIVES: To describe Russian rheumatologists’ disease managment of ﬁbromy-
algic patients. In fact, the Fibromyalgia Syndrom (FMS) is a disorder characterized 
by widespread pain and fatigue, and causes signiﬁcant morbidity to patients and 
their relatives METHODS: The questionnaire was sent to a random sample of 
Russian practitioners, who were answering the same questionnaire as that used by 
French practitioners in 2003. RESULTS: Seventy-seven percent of the practitioners 
claimed that they prescribed a medical treatment to their patients suffering from 
ﬁbromyalgia. Forty percent prescribed antalgics, 40% prescribed tricyclic antidepres-
sants, 29% serotoninergic antidepressants, 30% hypnotics/sedatives, 8 % homeo-
pathic treatments and a little over 1% morphine derivatives. Sixty-seven percent 
claimed that they prescribed extra treatments for their patients suffering from ﬁbro-
myalgia: 23% prescribed antalgics, 20% prescribed tricyclic antidepressants, 17% 
serotoninergic antidepressants, 24% hypnotics/sedatives, 9% homeopathic treatments 
and less than 1% morphine derivatives. A total of 82.6 % recommended or prescribed 
other treatments to their ﬁbromyalgic patients, namely: 36% acupuncture, 56% 
physiotherapy, 14% hypnotherapy, 36% spa treatment, 3% osteopathy and 38% 
relaxation techniques. 91.8% of the doctors advised regular physical exercise such as 
swimming and walking (71.9% and 65.6% respectively), with cycling being the activ-
ity least often advised, by 12.9% of the doctors. CONCLUSIONS: Treatment for 
ﬁbromyalgia must be multidisciplinary and multifactorial, its main objective being 
relieving the patient of their symptoms and allowing them to return to their profes-
sional and leisure activities —to which treatment of the condition by Russian practi-
tioners is a testimony.
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OBJECTIVES: PMO (prevalence: 7–30%) increases the risk of fractures, reduces life 
quality and expectancy, leads to loss of employment and creates signiﬁcant health care 
costs. Poor clinical outcomes have been associated with lack of adherence to treatment. 
This analysis assesses PMO patient adherence to bisphosphonate therapy in Germany. 
METHODS: Applying a systematic review of literature utilizing German-based data, 
we identiﬁed and analyzed nine studies assessing adherence to oral bisphosphonates 
published between 2005 and 2009. Our analysis considered persistence and compli-
ance associated with daily and weekly dosing regimens. Compliance was deﬁned as 
Medication Possession Ratio (MPR) ³80%. RESULTS: Only 10% of PMO patients 
in Germany are currently treated with bisphosphonates. Between 31.3% and 46.0% 
of patients discontinued therapy after the ﬁrst prescription. Studies showed poor per-
sistence to bisphosphonate therapy during the ﬁrst year (43.2%). The persistence 
during the ﬁrst year was lower with daily dosing compared with weekly dosing 
regimen (27.8–42% vs. 46.5–57%, respectively). Patients’ compliance varied from 
41.7–58.2% over the ﬁrst year. Reasons identiﬁed for poor persistence and compliance 
included inconvenience and frequency of administration, imperceptible efﬁcacy, and 
lack of patient education on the need for the medication. Non-compliance was primar-
ily due to side effects. Overall, studies concluded that poor adherence leads to greater 
economic burden due to higher fracture rates and increased hospitalizations. CON-
CLUSIONS: A signiﬁcant proportion of PMO patients discontinued and/or did not 
comply with therapy during the ﬁrst year, likely due to dosage inconvenience and 
frequency, and side effects. There is a need for treatments that patients consider more 
convenient and are associated with fewer side effects.
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OBJECTIVES: The objective was to analyse the exposure to osteoporosis medication 
(OPM) in men based on data from a health insurance company database. METHODS: 
The prescription-based database of the largest health insurance company of the Czech 
Republic (VZP CR) that covers about 65% of the Czech population was used as a 
source of data from 2002–2006. Health insurance is compulsory under Czech law. 
An insured male person with a recorded prescription for OPM (alendronate, risedro-
nate, calcitonin, strontium ranelate) in the year of interest was deﬁned as a patient 
and an insured male person with a recorded prescription for OPM in the years border-
ing the year of interest was deﬁned as a chronically treated patient. For the year of 
interest, the percentages of chronically treated patients without OPM medication as 
well as those with very low, i.e. 122 deﬁned daily doses (DDD)/year, low (122–243 
DDD/year) and adequate (243 DDD/year) medication adherence were determined. 
RESULTS: In 2002–2006, men accounted for less than 5% of OPM consumers. The 
total OPM and alendronate consumption rates were 0.6 and 0.3 DDD/1000 insured 
male persons/day, respectively. The number of male patients on alendronate more than 
doubled to 1123 in 2006. As many as 52% and 64% of the chronically treated patients 
fell into the adequate medication adherence group in 2004 and 2005, respectively. 
CONCLUSIONS: Signals of insufﬁcient osteoporosis treatment in the Czech male 
population were found. The increasing adequate medication adherence among the 
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chronically treated patients could be considered as a positive trend. The project was 
fully supported by grant No. 103107 from the Charles University Grant Agency.
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OBJECTIVES: Intravenous (iv) infusion of biologic agents is a highly effective thera-
peutic option in treating active Rheumatoid Arthritis (RA) patients. In Greece, it is 
mandatory that all infusions are administered in a hospital setting, therefore, they are 
strongly correlated with the system’s capacity in terms of resources. The objective of 
this study was to assess the capacity of the Greek National Health System (NHS) 
hospitals to meet current and projected demand for the iv treatment of RA patients. 
METHODS: Semi-qualitative interviews on the basis of a strictly structured question-
naire were conducted with the Heads of all NHS RA infusion sites, to record available 
resources (staff, equipment, facilities), service utilization and ability to meet current 
and projected demand. The questionnaire was externally reviewed and piloted to a 
small sample before administration. Data were analyzed using SPSSv15.0. RESULTS: 
From a total of 31 NHS infusion sites (rheumatology clinics, outpatient departments, 
pathology clinics, day clinics), 28 responded (Response Rate 90.3%). On average, 
41.6% of Greek NHS RA patients are treated with a biologic agent. 64.2% of respon-
dents stated that available resources are insufﬁcient to meet current demand. The most 
important constraints in selection order were: space (92.8%), staff (89.2%), equip-
ment (iv-pumps, beds and chairs—64.2%) and working hours (60.7%). A total of 
56% of respondents stated that they may decline treatment to patients due to capacity 
constraints. Overall, respondents estimated that the number of iv patients could be 
increased by 104% on average, were there no capacity constraints. CONCLUSIONS: 
An important proportion of the estimated 40.000 RA patients in Greece, for whom 
iv biologic treatment in the hospital setting is essential for disease control, may be 
declined treatment due to constraints in RA-speciﬁc resources. Rationalization and 
reallocation of NHS resources is required to ensure equity in access to effective treat-
ment for all RA patients.
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OBJECTIVES: Osteoporotic vertebral fractures (OVF) are an important health 
concern which remain underdiagnosed in 70% cases. According to recent data, 
approximately 450,000 and 700,000 symptomatic vertebral fractures are diagnosed 
each year in the EU and in the US, respectively. The aim of this study is to understand 
the perceptions of primary care physicians (PCP) with regards to diagnosis and man-
agement of OVF in their consultations. METHODS: Exploratory design using qualita-
tive methodology. 15 semi-structured interviews, recorded and later transcribed, with 
PCP between 2006–2007. Subsequently two investigators from the research team 
carried out the analysis and crosschecked results by identifying categories. RESULTS: 
Suspected diagnosis of OFV is based on anamnesis, physical examination and a simple 
X-ray. Physicians inform that this work is not executed systematically in daily con-
sultations and sometimes chronic back pain is not studied in depth. The differential 
diagnosis is perceived as a complex process, leading to confusion (back pain, osteo-
arthritis, rheumatoid arthritis and osteoporosis). PCP agree radiology is useful in 
detecting a vertebral fracture. PCP refer patients to other specialists when they ﬁnd 
difﬁculties reaching a diagnosis (history of fractures, repeated fractures, persistent 
pain, suspicion of secondary osteoporosis,etc) and also when they are not allowed to 
carry out a densitometry in their primary care health centre. Regarding this test, par-
ticipants described a lack of both consensus and shared guidelines in its use. Minimally 
invasive surgical techniques are not widely known about and their access is irregular 
even when medical treatments are ineffective. CONCLUSIONS: Some recommenda-
tions have recently been proposed for OVF management. This study has identiﬁed a 
mismatch between the proposed recommendations and the ordinary clinical practice. 
PCP´s diagnosis is inﬂuenced by their personal interest in the osteoporosis ﬁeld, the 
degree to which they rely on published evidence and the proximity of surgical teams 
involved in this area.
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Findings from Finckh et al., 2007 suggest that rituximab may be a better treatment 
to rheumatoid arthritis (RA) patients who made use of a previous anti-TNF agent. 
The results from Hyrich et al, 2007 point out that the reasons for RA patients stopping 
a second drug are related to the reasons for stopping the ﬁrst drug. OBJECTIVES: To 
picture the scenario of the usage of anti-TNFs as 2nd line therapy for RA patients in 
the public health care sector in Brazil. To calculate the economic impact of rituximab 
incorporation as 2nd line RA therapy. METHODS: A database analysis on the use of 
anti-TNFs as 2nd line therapy for RA patients was conducted for the total period 
(November 2006-january 2009) available at DATASUS (www.datasus.gov.br) the 
government public database. We were able to identify therapeutic pathways of 5018 
patients up to December 2007. About 2.5% (122 patients) performed a switch to a 
second anti-TNF agent. An increasing in the use of anti-TNFs as 2nd line therapy was 
also identiﬁed. Then the current economic impact of anti-TNF treatment switches was 
calculated. Later, we substituted the second-line anti-TNF agents used for rituximab 
and compared the results. Drug costs were obtained from ‘Banco de Preços em Saúde’ 
(http://portal.saude.gov.br/bps/), the government ofﬁcial source. RESULTS: The use 
of anti-TNFs as 2nd line therapy for RA patients in the public health care sector in 
Brazil is a reality with a growing trend in Brazil. The use of rituximab, as a replace-
ment of a second anti-TNF agent for RA patients, has the potential of offering savings 
of about R$2.5 million for the public health care sector. CONCLUSIONS: The use 
of rituximab, as a replacement for anti-TNFs agents as 2nd line therapy for RA patients, 
could increase the clinical beneﬁts for RA patients and bring savings of about R$ 2,5 
million for Brazilian public health care system.
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OBJECTIVES: The aim of this study was to evaluate retrospectively the average 
annual direct costs of treating patients affected by rheumatoid arthritis (RA) with and 
without concomitant pathologies. METHODS: Resource consumption and direct 
medical costs of patients with a diagnosis for RA were estimated using year 2007 data 
from the administrative database of Piemonte Region (4,401,266 inhabitants). Patients 
affected by RA were divided in two sub-groups: with Regional Health Service (RHS) 
concomitant exemptions due to other chronic pathologies (WE) and without concomi-
tant exemptions (WoE). Resource consumption measured was the following: reim-
bursed drugs, diagnostic procedures, hospitalizations (including day hospital). The 
analysis was performed from the RHS perspective. Unit costs considered were prices 
and RHS reimbursement tariffs. RESULTS: WoE Patients were 6616 while WE 
patients were 5056. Mean age in the WoE group was 58.54 while in the WE group 
was 66.50. Distribution by age class showed that patients younger than 46 years were 
about 19% of the WoE group and about 5.5% of WE patients; patients older than 
65 years were more frequent in the WE population (58% vs. 38%, respectively). 
Annual average cost of treatment per patient amounted to a2182.52 in WoE patients 
and to a3587.42 in WE patients. Drug cost amounted to 53% of total cost for WoE 
patients and to 44% in WE patients; hospitalization costs amounted to 24.9% of total 
cost for WoE patients and to 34% for WE patients; day hospital and diagnostic pro-
cedures amounted to around 7% and 15% respectively in both groups. CONCLU-
SIONS: The analysis of a large database showed that patients with RA are frequently 
affected by other important chronic pathologies and that patients affected by RA and 
WoE have an annual RHS cost 40% lower than patients affected by RA and WE.
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OBJECTIVES: There is a growing emphasis in understanding reimbursement decisions 
for Rheumatoid Arthritis (RA), which ultimately affect patient access to treatments. 
Despite a wide variety of treatment options there are still patients who do not achieve 
an adequate response. To analyse demand and supply side of RA treatment the effects 
of multiple factors on prescriptions decisions (as written by the doctors) and reim-
bursement (Reimb) such as logarithmized prescriptions (ln_Rx), relevant therapeutic 
classes (ATC), logarithmized prices (ln_Price) and sales (ln_Sales) and disease preva-
lence (Prev) will be determined. METHODS: According to the underlying dependent 
variables different model speciﬁcation has been used. To explore the multiple variables 
affecting RA prescription a mixed model has been implemented whereas to analyse 
the shares of RA reimbursement levels a logistic regression has been chosen. RESULTS: 
The analyses include 6 years period (2003–2008) of prescription data for the EU5 
covering all ATC classes prescribed for RA. We found signiﬁcant effects on reimburse-
ment for ln_Rx (0.1868,p  0.0001), ln_Price (0.0189,p  0.0001), and country 
(France  1.1934, Germany  0.2542, Italy  0.1914 and Spain  1.1066). On 
prescriptions the results are highly signiﬁcant for ln_Sales (0.1793,p  0.0001), Reimb 
(0.1718,p  0.0001), ln_Price (0.2576,p  0.0001), Prev (0.5012,p  0.0001), and 
77% of all ATC classes. CONCLUSIONS: The results show that reimbursement seems 
to be negatively inﬂuence by supply (e.g. high retail prices in Germany) and demand 
(prescriptions) effects. These results are in line with national cost containment endea-
vours of payors. However, different factors such as promotion of generic drug usage 
in UK or high pharmaceutical consumption per person as in France combined with 
low prices seem to have stronger positive effects on reimbursement then in Spain, 
Germany, or Italy. As expected sales and further reimbursement opportunities are 
positively inﬂuencing the prescription of RA drugs whereas increasing prices are 
reducing RA related prescriptions. Interestingly, we see signiﬁcant positive epidemio-
logical demand factors such as an increasing RA prevalence.
